EPS for Seattle Genetics, Inc. (SGEN) Expected At $-0.44; Fir Tree Increased By $1.80 Million Its Bonanza Creek Energy (BCEI) Stake

June 26, 2017 - By Marie Mckinney

Analysts expect Seattle Genetics, Inc. (NASDAQ:SGEN) to report $-0.44 EPS on July, 25.They anticipate $0.21 EPS change or 91.30% from last quarter’s $-0.23 EPS. After having $-0.42 EPS previously, Seattle Genetics, Inc.’s analysts see 4.76% EPS growth. About 149,999 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since June 26, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Fir Tree Inc increased Bonanza Creek Energy Inc (BCEI) stake by 89.42% reported in 2016Q4 SEC filing. Fir Tree Inc acquired 1.80 million shares as Bonanza Creek Energy Inc (BCEI)’s stock declined 82.37%. The Fir Tree Inc holds 3.81 million shares with $3.89M value, up from 2.01M last quarter. Bonanza Creek Energy Inc now has $591.06 million valuation. The stock increased 0.10% or $0.03 on June 23, reaching $29.05. About shares traded. Bonanza Creek Energy, Inc. (NYSE:BCEI) has declined 89.11% since June 26, 2016 and is downtrending. It has underperformed by 105.81% the S&P500.

Among 16 analysts covering Bonanza Creek Energy (NYSE:BCEI), 2 have Buy rating, 5 Sell and 9 Hold. Therefore 13% are positive. Bonanza Creek Energy had 42 analyst reports since July 28, 2015 according to SRatingsIntel. Deutsche Bank maintained the stock with “Hold” rating in Friday, August 5 report. Cowen & Co downgraded the shares of BCEI in report on Tuesday, September 8 to “Underperform” rating. The rating was maintained by Macquarie Research on Wednesday, March 2 with “Neutral”. The firm has “Hold” rating by Deutsche Bank given on Tuesday, June 14. The rating was downgraded by Macquarie Research on Monday, May 9 to “Underperform”. The stock has “Neutral” rating by Credit Suisse on Tuesday, March 8. The firm earned “Hold” rating on Friday, May 6 by Topeka Capital Markets. The stock has “Hold” rating by Deutsche Bank on Wednesday, December 9. The stock of Bonanza Creek Energy, Inc. (NYSE:BCEI) has “Buy” rating given on Monday, October 5 by Topeka Capital Markets. As per Monday, November 9, the company rating was downgraded by Raymond James.

Investors sentiment decreased to 0.43 in Q4 2016. Its down 0.08, from 0.51 in 2016Q3. It worsened, as 30 investors sold BCEI shares while 21 reduced holdings. 9 funds opened positions while 13 raised stakes. 31.50 million shares or 18.91% more from 26.49 million shares in 2016Q3 were reported. Citadel Llc invested 0% of its portfolio in Bonanza Creek Energy, Inc. (NYSE:BCEI). Fir Tree holds 3.81M shares. The Ontario – Canada-based Natl Bank Of Montreal Can has invested 0% in Bonanza Creek Energy, Inc. (NYSE:BCEI). Citigroup Incorporated has invested 0% in Bonanza Creek Energy, Inc. (NYSE:BCEI). Morgan Stanley holds 181,229 shares. 2.00M were reported by Vanguard Gru. Royal Bancorp Of Canada holds 384,317 shares. Walleye Trading Lc reported 6,632 shares. 368,476 were reported by Susquehanna Intll Group Limited Liability Partnership. Bnp Paribas Arbitrage Sa has 0% invested in Bonanza Creek Energy, Inc. (NYSE:BCEI) for 2,350 shares. Bancorporation Of Ny Mellon owns 1.37 million shares. Creative Planning reported 1,000 shares. Whittier stated it has 2,025 shares. Bridgeway Mgmt Inc reported 115,000 shares. Kbc Gru Nv invested 0% of its portfolio in Bonanza Creek Energy, Inc. (NYSE:BCEI).

Since January 4, 2017, it had 1 buying transaction, and 2 insider sales for $1.10 million activity. The insider FIR TREE INC. sold 5.57 million shares worth $2.96M. Another trade for 20,237 shares valued at $793,695 was made by WHITEBOX ADVISORS LLC on Monday, May 1.

Fir Tree Inc decreased Cdk Global Inc (NASDAQ:CDK) stake by 1.46M shares to 3.79M valued at $226.51 million in 2016Q4. It also reduced Microsoft Corp (NASDAQ:MSFT) stake by 174,800 shares and now owns 1.53M shares. Yahoo Inc (NASDAQ:YHOO) was reduced too.

Investors sentiment increased to 1.2 in 2016 Q4. Its up 0.20, from 1 in 2016Q3. It improved, as 30 investors sold Seattle Genetics, Inc. shares while 73 reduced holdings. 60 funds opened positions while 64 raised stakes. 135.77 million shares or 1.02% less from 137.16 million shares in 2016Q3 were reported. 2.18 million were reported by Artisan Prtn Partnership. 262,106 were reported by Credit Suisse Ag. Moreover, Emory University has 1.54% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Redmile Group Limited Liability Company owns 1.52 million shares. Cornerstone Advsr reported 150 shares. Principal Financial holds 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 72,842 shares. Invesco Ltd holds 0% or 155,183 shares. Ubs Asset Mngmt Americas Inc holds 188,705 shares or 0.01% of its portfolio. Metropolitan Life Insur Com New York reported 6,607 shares stake. Castleark Limited Liability holds 0.06% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 37,460 shares. Profund Limited Liability Company reported 42,529 shares. Calvert Mgmt holds 0.01% or 5,943 shares in its portfolio. Sumitomo Mitsui Inc reported 0.02% stake. Ftb Advisors Incorporated has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Moreover, Panagora Asset Mngmt has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 4,513 shares.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $8.60 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

Among 10 analysts covering Seattle Genetics (NASDAQ:SGEN), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Seattle Genetics had 20 analyst reports since July 31, 2015 according to SRatingsIntel. Credit Suisse downgraded the shares of SGEN in report on Monday, December 12 to “Neutral” rating. The stock has “Sell” rating by Goldman Sachs on Wednesday, November 18. The firm has “Neutral” rating by Piper Jaffray given on Friday, October 30. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, July 31 report. The firm has “Neutral” rating by Goldman Sachs given on Thursday, September 15. Morgan Stanley initiated the stock with “Overweight” rating in Wednesday, September 7 report. Oppenheimer maintained the shares of SGEN in report on Friday, June 2 with “Hold” rating. Barclays Capital downgraded Seattle Genetics, Inc. (NASDAQ:SGEN) on Tuesday, November 29 to “Equal-Weight” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by Cantor Fitzgerald on Wednesday, July 27. As per Friday, August 14, the company rating was maintained by Leerink Swann.